BMJ 2012;344:e615 doi: 10.1136/bmj.e615 (Published 2 March 2012) Cost effectiveness of strategies to combat vision and hearing loss in sub-Saharan Africa and South East Asia: mathematical modelling study Rob Baltussen senior researcher 1, Andrew Smith honorary professor 2 1Department of Primary and Community Care, Radboud University Nijmegen Medical Center, PO Box 9101 6500HB Nijmegen, The Netherlands;2Centre for Disability and Development, London School of Hygiene and Tropical Medicine, London, UK
Dans la pharmacie en ligne Viagra-représenté Paris large éventail de la dysfonction érectile anti-plus consommée. Générique Levitra (vardenafil), Cialis (tadalafil) et achat viagra pour homme, dont le prix est acceptable pour tous les budgets.1
Yo no soy un gran amante de pedir medicamentos por internet. Pero a veces la necesidad de herramientas, que en las farmacias regulares o no, o rara vez comprar cialis Recibes como un paquete, todo montado y embalado.
"CALL ATIC ON TOLL FREE NUMBER : 0800200055 FOR FREE ADVICE ON PATIENT MANGEMENT. YOU CAN ALSO BEEP OR SMS ATIC ON 0717326500
VOLUME : 8
Quarterly Newsletter of the AIDS Treatment Information Centre, Infectious Diseases Institute, Makerere University, Kampala Case Report: Skin Reaction to Tenofovir By Dr. Gyaviira Makanga (Mmed Int.Med) & Dr. Stella Zawedde - Muyanja (MBChB) A 30 year old female presented to a local HIV Care Centre in Kam- nevirapine dose was then escalated to 200mg BD, which she toler- pala, Uganda for Routine Counsel ing and Testing for HIV after her ated well for the next 2 months with a rise in CD4 to 487 cells/µl husband had tested HIV positive from another centre. She had no after 3 months on ART. The Nevirapine dosing was then escalated major complaints apart from a history of heavy menses, no prior ma- to 400mg OD. (once daily dosing of nevirapine has been found to jor opportunistic infections and physical exam was unremarkable.
have ARV efficacy similar to twice daily nevirapine and is recom-mended for treatment simplification) She underwent routine pre and post-test counselling and was found HIV positive on two rapid HIV tests i.e. determine and statpak Three days after the new dose, she reported back to the clinic with a respectively. She was initiated on cotrimoxazole prophylaxis and generalised itchy maculo-papular rash involving the oral mucosa as ferrous sulphate 200mg three times a day. Her baseline labs were smal blisters. Al her medications were stopped including cotrimox-as below; azole. She reported no herbal remedies used prior to the rash. No repeat laboratory tests were done. She improved within 2 weeks and was re-started on TRUVADA®/efavirenz. One day after medication, developed another generalised erythematous itchy maculo-papular rash but no mucosal involvement. The ART was stopped, with clear- ance of the rash within 4 days. One week later, was re-initiated on TRUVADA® and ALUVIA®. One day after this new medication, developed another generalised itchy macula-papular rash with mucosal involvement, she stopped her medication and reported back to the clinic. NB: The above are the basic initial laboratory tests done by the clinic, viral load, Hepatitis B and C tests are not routinely done Further consultation with colleagues at the AIDS Treatment Infor-due to cost. mation Centre (ATIC) located at the Infectious Diseases Institute, Makerere University; Kampala suggested the offending drug could Based on her CD4 cell count (<350), she underwent three pre-anti be tenofovir. A TRUVADA® switch was therefore suggested. retroviral therapy (ART) counselling sessions with the counselling team as per the Centre/Current ART guidelines and was initiated on One week later, she was counselled and re-initiated on AZT/3TC ART 2 months from time of first presentation.
(COMBIVIR®) plus ALUVIA® and cotrimoxazole was restarted. She did well on this new regimen with no further complication. She She was started on tenofovir/emtricitabine (TRUVADA®) plus ne- has continued to do well to-date with no further skin or mucosal virapine 200mg OD for 14 days, with no major adverse effects. Her adverse reactions.
continues on Pg 2 INSIDE THIS ISSUE :
Skin Tuberculosis Ethambutol Associated Filarial Diseases
Dr. Natalie Prevatt Coordinator; African Short Course in A typical day in the life of a healthcare worker will often find Tropical Medicine, London School of Hygiene and Tropical Medicine & Hospital for Tropical Diseases, UK them dealing with a rather wide range of health related issues, some similar and others unique to particular patients.
Dr. Philip Gothard Consultant Physician, Hospital forTropical Diseases, Mortimer Market Centre, Capper Street, This edition of the ATIC Newsletter reflects the life of a health London WC1E 6JB, UK .
worker that has to read up on different issues as they deal with different patients. Dr. Tom Doherty London School of Hygiene and Tropical Medicine & Hospital for Tropical Diseases, UK When most of us think of skin reactions to ARVs, Nevirapine and Efavirenz are the drugs that come to mind. In this article, we share with you a unusual case from Nsambya Home Care Editorial Committee HIV Clinic about a patient who got a skin reaction to Tenofovir. We also share with you another interesting Case Report from the Infectious Diseases Institute on Skin Tuberculosis.
Ceppie Merry HIV Physician and Pharmacologist, TrinityCollege Dublin and Infectious Diseases Institute Over the past months, a number of you have called ATIC with Prof. Walter Schlech Dalhouise University, Canada queries on how to manage patients with suspected Ethambutol Prof. Allan Ronald University of Manitoba, Canada toxicity and so we present you an article on Ethambutol asso-ciated Optic Neuritis in patients treated for Tuberculosis. We Mairin Ryan HIV Pharmacist and Pharmacoeconomist, IMB trust this will give you more information on the issue.
Kim Scarsi HIV Clinical Pharmacist, Northwestern MemorialHospital, Chicago Our special collaboration with the London School of Hygiene Charles Steinberg Consultant Training Department, Infectious and Tropical Medicine continues in this edition with more arti- Diseases Institute cles on the Neglected Tropical Diseases. This time, we bring you an article on the Buruli Ulcer, and another on Filarial diseases.
Leah Thayer Head of Training Department,Infectious Diseases Institute Please read on and learn from the different experiences and Sheila Karamagi ATIC Research and Communications information we have specially packaged for you.
Monica Amuha Grace ATIC – Pharmacist Sheila Karamagi – ATIC Research and Communications Stella Zawedde-Muyanja ATIC – Medical Officer & Team leader Skin and subcutaneous reactions i.e. urticaria, vesiculobul ous rash, pustular rash, maculopapular rash, pruritus and skin discol- oration are seen in one to ten out of 100 people taking Truvada. It is therefore plausible that the patient improved after discontinu- ation of Tenofovir. Although the culprit drug was later found to be Tenofovir, we should stress that NVP should be used with caution in women with CD4 cell counts above 250 due to increased risk of hepatotoxic- ty and that when a maculopapular rash occurs on NVP, patients Discussion :
should also be assessed for hepatotoxicity as the two adverse drug Although hypersensitivity skin reactions in HIV infected people are reactions tend to occur together. more commonly at ributed to cotrimoxazole and Non-Nucleoside Reverse Transcriptase Inhibitors ( NNRTIs), they can also be caused *Case is from a patient attending Nsambya Home Care HIV clinic* by Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs/ NtRTI), although with much less frequency. 15-27% of patients * The programme this patient was enrolled in uses the WHO 2010 receiving EFV and 17% of patients receiving NVP develop a rash cut off point of 350 to initiate patients on ART* compared to 9% of patients receiving CBV+3TC.
References • Once daily dosing of NVP versus twice daily dosing of NVP. Journal of The possibility of an NRTI or NtRTI causing a maculopapaular rash Antimicrobial Chemotherapy 2008 61( 1) 13-16 should be suspected if a rash does not resolve with discontinuation • www.medicines.ie : Truvada : Summary of Product Characteristics of cotrimoxazole and the NNRTI component of an ART regimen. • Medical Management of HIV Infection: Drug information: Nevirapine and Efavirenz
Skin Tuberculosis: A Case Report John Mark Bwanika1 ; Esther Nasuuna1*; Robert Lukande2 ; Yukari C. Manabe1,3 1. Research Department, Infectious Diseases Institute, Key words: Cutaneous Tuberculosis. Makerere College of Health Sciences, Kampala Corresponding author: Esther Nasuuna P.O Box 22418, 2. Department of Pathology; Makerere University of Mulago Hospital Complex, College of Health Sciences. Kampala Uganda 3. Division of Infectious Diseases, Department of Medicine, Johns Hopkins School of Medicine, Tel; +256-414-307200 / +256-701-620063 Baltimore, Maryland, USA. Abstract.
We report a case of primary cutaneous tuberculosis (lupus vulgaris) Fig 1
from the Infectious Diseases Institute, Mulago Hospital Complex, Kampala, Uganda.
A 28 year old, HIV positive woman presented with a four month history of large leg ulcers, fever and night sweats.
A wedge biopsy of the ulcer revealed stratified epithelium with foci of acathosis, ulceration of the epithelium and stroma with The physical exam was otherwise normal including the respira- numerous Langerhans giant cells, necrosis and epitheloid cells tory system. Laboratory testing revealed a normal complete blood with ill-defined granulomas.
count, normal renal & liver function tests, normal chest radiograph The patient was started on anti-tuberculous drugs and has had ex- and sputum was negative for acid fast bacilli.
cellent clinical response.
Purulent material gathered from the ulceration was cultured and Case History
identified as pseudomonas aeuruginosa that was sensitive to gen- A 28 year old woman who first presented to the Infectious Diseases tamicin and piperacillin tazobactam and resistant to ciprofloxacin Institute (IDI) clinic in August 2010 with a four month history of and cefepime.
spontaneous, progressively enlarging ulcers on the anterior aspect of the left leg. At that visit, she was tested and found to be HIV A skin biopsy was performed which showed stratified epithelium with positive with a CD4+ cell count of 295 cells/μl.
foci of acanthosis, ulceration of the epithelium and stroma with numer- ous Langerhan giant cel s, necrosis and epitheloid cel s with il defined She also had an intermittently productive cough, persistent evening granulomas consistent with lupus vulgaris ( see figures below) .
fevers, drenching night sweats and poor appetite. She also reported a 2-week history of voice hoarseness during that period.
She reported no history of weight loss, no history of trauma preced- ing the ulcers. She had no prior history of TB disease or treatment and had no known contact with a TB patient.
She had used various oral antibiotics but with no improvement in the leg ulcers.
As a result of this biopsy and the culture, the patient was diagnosed On physical exam, she was in good general condition, no wasting, with primary skin TB with pseudomonal super infection and treated temperature was 37.4C. She had oral candidiasis, no lymphadenop- athy, no figure clubbing.
with a 4–drug oral anti–TB therapy (ethambutol, rifampicin, pyra-zinamide and isoniazid) and also intravenous gentamicin 160mg Examination of the lower extremities revealed two large irregular daily for 5 days. Two weeks later, she was started on zidovudine, ulcers on the inferior aspect of her left leg measuring 5cm x 4cm lamuvudine and efavirenz (CBV/EFV) combination anti-retroviral with undermined edges. The ulcer base had a light greenish dis- therapy. Over the next 16 weeks, there was marked improvement of charge (see figures 1& 2 ).
the symptoms and ulcer regression (see figures 6 and 7 ). continues on Pg 4 Lupus vulgaris is a persistent, chronic skin ulceration. Lesions ap- pear in normal skin as a result of direct extension of underlying tu- berculous foci, of lymphatic or hematogenous spread, after primary inoculation , BCG vaccination or in scars of old scrofuloderma3.
Definitive diagnosis is made histologically. The pathologic hall- mark is an epitheliod granuloma with central caseation necrosis4.
In this case the patient had chronic ulcers that were treated with many courses of antibiotics without improvement. This scenario of Tuberculosis (TB) is an airborne, communicable disease that oc- chronic, non–healing ulcers in an HIV (+) patient led the attending curs after inhalation of infectious droplets expelled from patients physician to suspect and investigate for cutaneous TB. The sugges- with laryngeal or pulmonary TB during coughing, sneezing or tive biopsy results and the excellent clinical response to anti–tuber- culous medications further secured the diagnosis.
speaking. The most common site of the primary lesion is within alveolar macrophages in sub-pleural regions of the lung. Although Non–healing ulcers in a setting of endemic, high burden TB should mycobacteria are spread by blood throughout the body during ini- warrant further biopsy-driven investigation for skin tuberculosis tial infection, primary extra-pulmonary disease is rare except in especially in the immunocompromised.
severely immunocompromised hosts.
Cutaneous tuberculosis is invasion of the skin by mycobacterium The authors would like to grateful y acknowledge the patient and the tuberculosis and it is an uncommon form of extra-pulmonary TB. staff of the IDI clinic. Funding for John Mark Bwanika and Yuka C. It is more common in crowded parts of India and china. In Uganda Manabe has been provided from the National Institute of Health, DMID and in particular at the Infectious Disease Clinic where 400 HIV under the Tuberculosis Clinical Diagnostics Research Consortium. patients are seen daily with 30 of these in TB Clinic, no such case has been reported before. 1 .Dwari BC, Ghosh A, Paudel R, Kishore P. A clinicoepidemiological study This may be due to limitations in diagnostic capacity but also as a of 50 cases of cutaneous Tuberculosis in a tertiary care teaching hospital in pokhara,Nepal. Indian J Dermatol, 2010 Jul-Sep; 55(3)233-7 (PUBMED) result of the very low index of suspicion among clinicians. Even 2. Monte S Meltzer, Carol A Nacy, Cutaneous Tuberculosis (eMedicine in areas with high TB prevalence, it occurs in less than 0.1% of Dermatology) TB patients1,2. It has four common presentations that is; verrucosa 3. Bravo FG, Gotuzzo E.cutaneous tuberculosis. Clin Dermatol. cutis, lupus vulgaris, scrofuloderma and tuberculoid.
4. Fariña MC, Gegundez MI, Piqué E, et al. cutaneous tuberculosis: a clinical, histopathologic, and bacteriologic study. J Am Acad Dermatol. Verrucosa cutis occurs after direct inoculation of TB in the skin of 1995;33(3):433–440.
a previously infected person. It presents a purplish or brownish red observations of cutaneous tuberculosis in Larkana, Pakistan. Int J Dermatol. warty growth on the knees, feet and buttocks.
Buruli ulcer By Dr. Natalie Prevatt
Buruli ulcer is a necrotizing disease of skin and soft tissue. It is caused by an environmental mycobacterium named Mycobacterium ulcerans. M ulcerans produces a toxin called mycolactone that has cytotoxic properties, which cause tissue necrosis (death of body tissue). Mycolactone is also im- munosuppressive, and patients do not therefore present with fever or lymph- Over weeks/months a nodule or papule breaks down into a necrotic ulcer Nodule (Buruli commonly begins as Plaque (occasional y it starts as a skin plaque) a 1-2cm nodule) What are the differentials?
Buruli ulcer was first described in Buruli, Uganda (now Nakason- Early infection may look like an insect bite or pimple, psoriasis, gola district) but has been reported in numerous African countries, or leprosy. in Asia and Australia. Children under 15 years are most at risk in Africa. Infection rates are equal for males and females.
The nodule can be mistaken for a cyst, lipoma, or onchocercoma. Later it may appear similar to cutaneous leishmaniasis and TB, or M. ulcerans live in slow moving or stagnant water, the exact trans- the ulcer may appear like a venous ulcer or tropical ulcer, or as a mission method is unconfirmed but is assumed to be through con- deep fungal infection.
tamination of pre-existing minor wounds.
Buruli ulcer patients are not sick or febrile but the ulcer may be- Human to human transmission is very rare. The true prevalence of come secondarily infected leading to sepsis or tetanus.
Buruli ulcer is not known because there is underreporting and the variable presentation means that health workers often mistake it for other things. Is Buruli Ulcer more common in HIV?
Although Buruli is a mycobacterial infection there is little evidence Is Buruli ulcer dangerous? to suggest higher rates in HIV positive patients.
There is a low mortality rate, but because infection extends deep into fascia, muscle and bone it often leads to permanently restricted How do you confirm the diagnosis?
function and considerable morbidity. The scars left behind also A direct smear of exudate from the necrotic base of the ulcer (or have a social and emotional impact on the patients' life. under the edge) should be sent for ZN stain. This may show acid- fast bacilli. ZN stain only has 40% sensitivity and so if negative it How does buruli ulcer present? should also be sent for culture.
Lesions are normally on the limbs, especially the legs.
Culture is performed between 30-33 C (lower than for M.tb) and Buruli begins as a small firm nodule which is mobile in the subcu- takes 6-8 weeks on Lowenstein-Jensen medium. Culture has around taneous fascia, or sometimes as a painless papule (in the dermis), 40% sensitivity.
or an elevated dry plaque. This is occasionally pruritic. In a period ranging from days to weeks it begins to ulcerate.
PCR of biopsy specimens has very high sensitivity >90% and pro- vides results in 48 hours. PCR diagnosis is being rolled out in some African reference laboratories but is not available in the field.
Biopsies taken at operation can also confirm the diagnosis where culture does not rule out other causes.
Do you need to confirm the diagnosis?
Diagnostic confirmation is a long process with low sensitivity. Many patients present after ulceration has occurred. The ulcer is Treatment must be started early and so diagnosis is most often made large, but remains painless. It usually has scalloped borders and based on epidemiological and clinical acumen. necrotic slough in the base. A Buruli ulcer has an undermined edge and thus the lesion appears smaller than it really is. It may destroy Management
vessels, nerves and bone. From here M. ulcerans can spread via Medical (all stage treatment) lymph or blood to another site and satellite ulcers may develop In 2004 WHO reported the effectiveness of specific antibiotics - the recommended treatment is now directly observed rifampicin and Lesions eventually heal with disfiguring scars and contractures.
streptomycin with or without surgery. *less frequently an oedematous form may be seen which starts as a painful non–pitting oedmatous area. Side effects
Adults: 10mg/kg/day up to 600mg/day PO Gastro intestinal symptoms, flu like symp- Children: 10-20mg/kg/day up to 600mg/day PO toms, headache, altered liver functionbodily secretions e.g. urine turn orange/red colour Adults: 15mg/kg up to 1g OD Children: 15mg/kg up to 1g OD Nephrotoxicity, neurotoxicity, diarrhoea Ciprofloxacin or clarithromycin can be used as alternative to IM streptomycin– studies show no significant difference in regimes Adapted from WHO guidance 1
continues on Pg 6 There is no vertical Buruli ulcer programme in Uganda. Thus treatment should be given in local health centres, district and referral hospitals, without delay. WHO suggests that in endemic countries such as Uganda treatment should follow a protocol, which is seen here divided into 3 categories: Form of disease
Small early lesion (nodules/papules/ Start antibiotics at least 24 hours before plaques/ulcers <5cm diameter) surgery and continue for 4 weeks Schedule immediate excision and suture If cannot excise then treat with same anti- biotics for 8 weeks Large ulcerative lesions (>5cm), Give 4 weeks antibiotics before surgery Reduce extent of surgery (then surgery if still required) oedematous/plaque forms (ulcerative/ followed by another 4 weeks antibiotics lesions on the face/head/neck Mixed/ disseminated disease including Start antibiotics at least 1 week before Reduce extent of infection surgery and continue for 8 weeks before surgical excision Amended from WHO table 1
Although this recommendation was based on observational stud-ies, a recent RCT in Ghana 2 showed this treatment to be very ef-fective for patients with small early lesions: 96% of patients treated with eight weeks of rifampicin and streptomycin had healed le-sions at one year.
Surgical (late stage treatment)
Nodules/ papules and small ulcers are excised and closed.
Large ulcers are excised and closed with skin grafts. The addition of rifampicin and streptomycin to surgery has reduced recurrence rates ten fold 2.
(1) Provisional guidance on the role of antibiotics in the management of myco- After treatment
bacterium ulcerans disease (buruli ulcer). WHO (World Wide Web document) Ultrasound can be used to assess extension of ulcers under the skin Retrieved 1/2/11 from ht p:/ www.who.int/buruli/information/antibiotics/en/and thus response to treatment. (2) Nienhuis, W.A. and Stienstra, Y. et al. 2010. Antimicrobial treatment for early limited Mycobacterium ulcerans infection: a Randomized Control ed Trial. Lancet. 20;375(9715):664-72 There is some evidence that BCG vaccination is protective but only for a short time. The Global Buruli Ulcer Initiative3 aims to im- (3) Global Buruli Ulcer Initiative. In: Surveillance and control of Mycobacte- rium ulcerans disease (Buruli ulcer). In: Fifty-seventh World Health Assembly, prove the situation by increasing awareness among health profes- Geneva, 17–22 May 2004. Resolutions and decisions. Geneva, World Health sionals and encouraging early clinic attendance for patients with Organization, 2004 (WHA57/2004/REC/1):1–2.
suggestive early lesions.
Gill, G.E & Beeching, N.J. (2008) Lecture Notes on Tropical Medicine. 5th Major advances are only likely to be made when a rapid diagnostic Ed. Oxford. Blackwell Science. test becomes available for early disease.
Buruli Ulcer. WHO web page: http://www.who.int/buruli/en/ Dr Jenny Goldblatt Three diseases caused by filariae can affect people in Uganda; phatic Filariasis (LF), 13 million of who live in Uganda. It is these are lymphatic filariasis, onchocerciasis, and loa loa (figure estimated that the disease disfigures a third of people infected.
1). They are all spread by insect vectors. Whilst not fatal they do cause chronic conditions which impact on patients' quality of life Vector: Mosquito species (Aedes, Anopheline, Culex, Mansio-
and their economic and social functioning. It is important to dis- nia or Ochlerotatus) cuss the filarial diseases at the same time because the treatments used to kill one type of filariae can cause serious and sometimes Major features: Lymphoedema of the limbs, genitals or breasts,
fatal reactions in patients infected with another. progressing to elephantiasis. Complications include bacterial super-infection and "filarial fevers" (acute exacerbations) char- Life of filariae inside humans
acterised by headache, malaise, pain and fever. Filarial larvae gain entry to humans through the bites of infected insects. They migrate into the body to mature into adults over Disease course: Infection is usually acquired in childhood.
a number of weeks. Adults produce millions of microfilariae Lymphoedema can develop several decades later and is caused which can be found in many types of bodily fluid including blood by damage to the lymphatics from recurrent attacks of lymphan- and CSF. The vector ingests the microfilariae when biting, thus gitis due to dying adult worms. Superimposed bacterial infec- continuing the life cycle.
tions contribute to the severity of lymphedema from inflamma- tion and fibrosis and subsequent progression to elephantiasis.
The complications of filarial infections often result from ineffec- tive immune defense leading on to chronic carriage and inflam- Oedema: Thrombophlebitis, venous thrombosis, cellulitis, bac-
terial lymphangitis, proximal lymphatic occlusion, heart failure, cirrhosis, nephrotic syndrome.
Lymphatic Filariasis (Wuchereria bancrofti)
Scrotal Swelling: epidydimo-orchitis, abscess formation, hernia, varicocoele, congential hydrocoele, epididymal cyst, testicular An estimated 120 million people worldwide are at risk of Lym- continues on Pg 8 Diagnostic tests:
If filarial fever occurs patients should take antipyretics and antibi- Filariasis is diagnosed by identifying microfilaria on giemsa otic treatment if bacterial skin infection is present. Patients should stained blood film smears. Blood should be drawn at night (when be advised against cutting the skin. The WHO produces educa-the vector is expected to bite), diagnosis can also be made with a tional material for healthcare workers and patients on this topic. card-based antigen detection kit.
If you have any more concerns about filariasis, you can contact
ATIC on 0800200055
The mainstay of management is preventing complications: Advice There are limited trials that examine optimal drug treatment as part of
the patient to keep the affected area clean by washing with clean filariasis management. Current recommendations are based on lim-
ited trials and expert opinion. Adult worms are kil ed with the use of water and soap, drying carefully and avoiding injury to the skin. Diethylcarbamazine DEC for 21 days, though this does not reverse
Affected limbs should be elevated where possible and patients existing changes (see table 1). DEC must be used with caution if co- should exercise to aid lymphatic drainage.
infection with onchocerca volvulus is possible (see Onchocerciasis).
Table 1: Doses of medications commonly used in filarial disease
Lymphatic filariasis Treatment
Diethylcarbamazine (DEC) 1mg/kg first day, building up over 3 days to 6mg/kg/day (in 3 doses) for 21 days Control (appropriate to 400mg taken once 150 mcg / kg taken onceWeight Number of tablets Treatment and control As for LF. Repeated every 6-18 months for several years.
Treatment of adult worms 200mg OD for 6 weeks (doxycycline not in (with Ivermectin) children <12 or pregnant women) 1mg/kg first day, building up over 3 days to 6 mg/kg/day (in 3 doses) for 21 days Prevention - Mass Drug Administration (MDA)
ern borders of the country This includes areas like Arua, Yumbe, In the past, there has been annual mass treatment to prevent LF Moyo , Adjumani, Hoima, Kasese and Kisoro across Uganda, using Ivermectin and Albendazole. This programme is no longer active. It is recommended that population based treat- ment programmes are repeated annually for 5-6 years. Onchocerciasis is spread by blackflies (Simulium sp), which live near fast flowing water. Bites are very painful. Onchocerciasis (river blindness)
Nearly 3 million people live in regions of Uganda in which oncho- Patients complain of intensely pruritic skin. This itch is due to cerciasis is endemic. These are largely those areas along the West- death of microfilariae as they migrate through tissue. As patients continuously scratch, the skin of the thighs and buttocks becomes Surgical removal of skin nodules can be performed. lichenified and depigmented and loses its elasticity. This dermatitis progresses to atrophy where the typical hanging groin can be seen.
Community directed MDA programmes
There are several manifestations in the eye including sclerosing Some community directed programmes using Ivermectin have been
keratitis, cataract formation and optic atrophy, all of which can established in parts of Uganda where there is a higher risk of On-
cause blindness. Eye disease usually starts as an itchy red eye due chocerciasis.
to inflammation triggered by parasite migration.
The Onchocera volvulus adults may lie in subcutaneous nodules. Loa Loa
These are often seen near bony prominences which the worms have Importance:
been unable to pass by.
People infected with Loa Loa can have serious adverse reactions such as encephalopathy and retinal haemorrhage if treated with Ivermectin. Loa Loa is know to be prevalent in Central and West Skin manifestations: atopic dermatitis, contact dermatitis, chronic Africa, including regions bordering Uganda, and has previously
eczema, malnutrition, loa loa, superficial mycoses, streptocerciasis, been reported in Uganda, so it is important to be vigilant for evi-
dence of this disease in areas in which Ivermectin may be given.
Ocular manifestations: glaucoma, trachoma, cataract
Vector: Mango Fly (Chrysops sp).
Infected individuals are often asymptomatic. Localised, sudden onset Skin snips are taken from near a nodule or a high yield area such and short-lived inflammation may occur as a result of migration of as the thigh. The skin is lifted with point of a needle and a 1mm adult worms through the subcutaneous tissues. This Calabar swel -scalpel snip is collected and sent to laboratory in saline to look for ing, often at the wrist, is reported by the patient as a swel ing which microfilarae and typical histological changes. Serology does not appeared and disappeared leaving no trace. Worms may visibly mi-distinguish between past and current infections.
grate under the sclera of the eye, which is distressing for the patient. Management:
Differential Diagnosis of Calabar swelling:
The mainstay of treatment is Ivermectin (see table 1). This can im- Reactive arthritis, onchocerciasis, idiopathic angioedema prove both ocular and dermatological manifestations. Ivermectin
prevents production of microfilaria (but has no action against adult Diagnostic tests:
worms, which can live in humans for around 12 years, and so treat-
Visualisation of microfilariae in blood taken at noon when the vec- ment must be repeated every 6-18 months for a number of years. tor is most likely to bite. Serology has been used for population screening.
Doxycycline has some activity against adult worms and can be giv-
en at a dose of 200mg daily for 6 weeks in addition to Ivermectin Treatment:
but not in children under 12 years.
DEC can be used against adult worms (see table 1). Encephalitis has been reported in patients with high microfilarial loads due to Treatment carries a risk of al ergic / inflammatory reactions which death of migrating worms. can lead to facial oedema, anterior uveitis, keratitis, tachycardia and postural hypotension as wel as myalgia, lymphadenopathy, syno- Adults migrating across the eye can be removed surgically if it is vitis and headache. Although this is markedly more common with not possible to do this with the corner of a piece of paper.
DEC, particularly in the malnourished, 1-5% of those treated with Ivermectin alone may also be affected. Interaction with HIV
There is no clear evidence of significant interaction between HIV
The use of low dose dexamethasone (3mg/kg) may reduce the severity and filarial infections, though there is experimental evidence to of this reaction without reducing anti-microfilarial activity. Ivermectin suggest that lymphocytes from those infected with filariae may be is not safe for pregnant women, lactating mothers, children younger more susceptible to HIV infection.
than five years and people with heart, liver and kidney diseases.
Adults larvae produce millions of microfilariae which can be found in many types of bodily fluid including blood and CSF. Ethambutol Associated Optic Neuritis : One Of The Side Effects To Look Out For In Patients Treated For TuberculosisMonica Amuha Grace B.Pharm, MPS Ethambutol is a synthetic antituberculosis agent used in com- Patients who develop optic neuritis may complain of bilateral bination with other antituberculosis agents in the treatment of progressive painless blurring of vision or decreased color per- clinical Tuberculosis (TB). Tuberculosis caused by Mycobac- ception. Some individuals may be asymptomatic with abnor- teruim tuberculosis, is a major cause of morbidity and mortal- malities detected only by vision tests.
ity in Uganda. Uganda was ranked 18th out of the 22 tuber- culosis high-burden countries in the world during 2009. The Examination by an ophthalmologist may reveal pupils that are incidence of TB is 330/100,000 population for all TB cases and bilaterally sluggish to light, decrease in visual acuity with mini- 136/100,000 population for sputum smear-positive pulmonary mal or no light perception, constriction of visual fields, areas of TB. The Annual Risk of TB Infection (ARI) for Uganda is esti- diminished vision within the visual field( scotomas), and loss of mated at 3 percent. red-green color discrimination which may be the earliest sign The interaction between TB and HIV is increasing the burden of both diseases. HIV is one of the major risk factors for the development of active TB among individuals infected with My- Characteristics of ocular toxicity of ethambutol
cobacterium tuberculosis. At present, an estimated 60% of TB The extent of ocular toxicity appears to be dose and duration re- patients in Uganda are also infected with HIV. TB accounts for lated. However, such toxicity has also been reported rarely only 30 percent of all deaths among HIV positive patients.
after a few days of therapy with the drug.
The recommended first line anti-tuberculosis agents used in Dose-related
management of TB include; rifampicin(R), Isoniazid (H), The reported incidence of ethambutol-related optic neuritis var- Pyrazinamide(P) and Ethambutol(E). ies between 18% in patients receiving more than 35 mg/kg per day, 5% to 6% with 25 mg/kg per day, and less than 1% with The current WHO 2010 TB guidelines no longer recommend an 15 mg/kg per day ( the recommended dose) of ethambutol for 8 month regimen of 2RHZE and 6EH as the first line treatment more than 2 months. 50% of ethambutol is excreted in urine, for tuberculosis in adults. They instead recommend a 6 months therefore patients with poor renal function are at higher risk of regimen containing 2RHZE and 4RH . This is because the use of ocular toxicities. rifampicin for only 2 months in the intensive phase was associ- ated with a high rate of relapses and deaths.
The manifestation of ocular toxicity is usually delayed, and gen- However, in Uganda we are yet to adopt this recommendation erally does not develop until at least 6 weeks after treatment. and are still using an 8 months regimen of 2RHZE/6EH. With The mean interval between onset of therapy and toxic effects this regimen, there is a longer duration of exposure to ethambu- has been reported to be 3 to 5 months. However, manifestations tol thus increasing the risk of ethambutol associated side effects. of toxicity as late as 12 months after therapy initiation have also Ethambutol has several side effects that include optic neuritis, headache, malaise, dizziness, mental confusion, fever, abdomi- Other factors that predispose subjects to toxicity include nal pain, anorexia, nausea and vomiting and more rarely periph- diabetes and optic neuritis related to tobacco and alcohol eral neuritis, rash, pruritus, urticaria, hepatitis and thrombocyto- consumption.
penia. The most important of these is optic neuritis. Management
Patients in whom ethambutol is relatively contraindicated should Where possible patients commencing treatment with ethambutol be identified before initiation of TB treatment. These include pa- should have a baseline eye examination including best corrected tients who are unlikely to notice or describe visual symptoms, visual acuity, color vision and visual field. These parameters such as patients with dementia, mental retardation and children. should then be monitored periodically (every 1 to 3 months) .
In some of these patients e.g. children below 12 years, etham- butol should be avoided, (recommended first line regimen for Outcome
children below 12 yrs is 2 months of RHZ and 4 months of RH) When ocular toxicity is detected early and ethambutol is discon- and in others pharmacovigilance should be encouraged. tinued promptly, the visual effects are generally reversible over a period of weeks or months. Rarely, depending on the degree of The dose of ethambutol must always be carefully calculated on impairment, recovery may be delayed for up to 1 year or more, a weight basis and the dose or the dosing interval should be ad- or the effect may be irreversible. Care should be taken to be justed based on creatinine clearance in patients with impaired renal function. If creatinine clearance is between 10-50ml/ certain that variations in vision are not caused by underlying minute: administer 15mg/kg of ethamutol every 24-36 hours, pathologic conditions such as cataracts, diabetic retinopathy or if creatinine clearance is <10ml/minute administer 15mg/kg of CMV retinitis in HIV positive individuals. ethamutol every 2 days. Patients treated with ethambutol should be educated on the pre- 1. AHFS Drug Information 2009, American Society of Health System Phar- senting sign and symptoms of ocular toxicity i.e. blurred vision macists. Page 576-578 2. Drug Information Handbook, A comprehensive Resource for all Clinicians and/or decreased colour perception. They should promptly seek and Healthcare Professionals 18th Edition, 2009-2010. page 573-574 medical advice if their sight or perception of color deteriorates. 3. Ministry of Health Manual of The National Tuberculosis and Leprosy Pro- In this case, ethambutol should be stopped and replaced with gramme: 2nd edition 2010 streptomycin during the intensive phase and rifampicin and iso- 4. Treatment of Tuberculosis Guidelines Fourth edition WHO 2010 niazid should be given for the continuation phase for 4 months.
5. www.bnf.org BNF 61 March 2011 ATIC Dr. Stella Zawedde-Muyanja. MBChB
As a Quality Improvement advisor at health centers in Eastern Uganda, I have observed some
challenges in provision of antiretroviral therapy (ART) at the facilities I supervise.
Due to challenges in logistics management, some health centers experience occasional stock outs of
antiretrovial drugs (ARVs) ranging from single drug formulations to fixed dose combinations.
This often leads to rationing of the available ARVs for clients as providers wait to receive more stocks.
Sometimes, this rationing leads to treatment interruptions for varying durations among HIV/AIDS
clients on antiretroviral therapy.
Are there risks of resistance associated with such unplanned interruptions in antiretroviral therapy ?
If so, after what duration of interruption do you anticipate emergence of resistance and recom-
mend change in treatment regimen ?
Yes there are.
Treatment Interruptions whether planned or unplanned are not recommended during Antiretroviral Therapy. Evidence that treatment interruptions are not a good treatment option comes from previous clinical trials that explored different treatment interruption schedules One of these clinical trials was a randomized trial nested within a bigger trial (the DART Trial) . This trial compared fixed length Structured Treatment Interruption and Continuous Treatment in adults on first line Antiretroviral Therapy (ART). Patients who had been on ART for more than 48 weeks and were clinically stable with CD4 cell counts above 300cells/ul were randomized to continue taking ART continuously or to undergo Structured Treatment Interruptions with repeated 12 week periods on or off therapy This trial was stopped early because patients in the structured treatment interruption arm had a greater risk of disease progression and more HIV related complications than patients in the continuous treatment arm. Trials of treatment interruption done in other countries produced similar results with more deaths, drug related complications and HIV related events in patients who underwent the treatment interruption. The speed at which resistant mutations emerge after treatment interruption depends on the type of ART regimen and the mode of discontinuation.
Patients whose treatment gets interrupted while on Non-Nuleoside Reverse Transcriptase Inhibitor (NNRTI) based regimens develop resistance (to the NNRTI component) very quickly. This is because the NNRTIs (efavirenz and nevirapine), have very long half lives and stay in the bloodstream longer than the Nuleoside Reverse Transcriptase Inhibitors (NRTIs). Patients are in effect exposed to monotherapy with NNRTIs which leads to resistance. The situation is worse if the ART regimen is stopped without a twoweek lead out dose of the NRTIs. This is unfortunately what happens in most cases of unplanned A study done in Kampala , which followed up HIV-positive, antiretroviral-naive individuals initiating ART on stavudine, lamivudine and nevirapine for 24 weeks, found that treatment interruptions were significantly associated with drug resistance. At the end of this study, none of 33 participants who did not interrupt treatment for over 48 h had drug resistance, whereas eight of 62 (13%) participants who did interrupt therapy experienced drug resistance. It is therefore important for all personnel involved in ART care to realize that they should do their best to ensure continuous supply of ART so that their patients can continue their treatment without interruption. A few measures that healthcare workers can put in place to achieve this are ; • Submitting drug order forms to the district focal person and to National Medical Stores (NMS) in a timely manner to facilitate drug processing and delivery. • Accurate quantifying their drug needs so that all patients on their programme are catered for References:
Medical Management of HIV infection 2009-2010 Edition: Pages 109-111 Fixed Duration Interruptions are inferior to continuous treatment in African Adults starting therapy with CD4cell counts < 200 cells/ul. The DART Trial Team AIDS 2008, 22: 237-247 Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda Jessica H. Oyugi, Jayne Byakika-Tusiime, Kathleen Ragland, Oliver Laeyendecker, Roy Mugerwa, Cissy Kityo, Peter Mugyenyi, Thomas C. Quinn and David R. Bangsberg, AIDS 2007, 21:965–971
Anti-libidinal medication and people with disabilities : long-term follow-up outcomes following third party consent to medication for problematic sexual behaviour
Anti-libidinal medication and people with disabilities – long-term follow-up of outcomes following third party consent to medication for problematic sexual behaviour CRC 38/00-01 REPORT TO THE CRIMINOLOGY RESEARCH COUNCIL AUGUST 2002 Associate Professor Susan Hayes, AO, PhD Fiona Barbouttis, BA, GDS (Psych)